Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute LymphOblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP/Grp78 and Turning on the Pro-apoptotic NF-κB
Author
McCubrey, James A.
Date
2016-01-12
Citation:
APA:
McCubrey, James A.. (January 2016).
Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute LymphOblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP/Grp78 and Turning on the Pro-apoptotic NF-κB.
,
(),
-
. Retrieved from
http://hdl.handle.net/10342/9588
MLA:
McCubrey, James A..
"Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute LymphOblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP/Grp78 and Turning on the Pro-apoptotic NF-κB". .
. (),
January 2016.
April 26, 2024.
http://hdl.handle.net/10342/9588.
Chicago:
McCubrey, James A.,
"Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute LymphOblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP/Grp78 and Turning on the Pro-apoptotic NF-κB," , no.
(January 2016),
http://hdl.handle.net/10342/9588 (accessed
April 26, 2024).
AMA:
McCubrey, James A..
Synergistic Cytotoxic Effects of Bortezomib and CK2 Inhibitor CX-4945 in Acute LymphOblastic Leukemia: Turning Off the Prosurvival ER Chaperone BIP/Grp78 and Turning on the Pro-apoptotic NF-κB. .
January 2016;
():
.
http://hdl.handle.net/10342/9588. Accessed
April 26, 2024.
Collections